Abstract:Background Parkinson’s disease (PD) therapeutic strategies have evolved since the introduction of levodopa in the 1960s, but there is limited data on their impact on disease progression markers. Objective Delineate the current landscape of PD progression at tertiary subspecialty care and research centers. Method Using Accelerating Medicine Partnership-PD (AMP-PD) data harmonized from seven biomarker discovery studies (2010-2020), we extracted: overall [Schwab and England (S&E), PD Questionnaire (PDQ-39)]; motor [Movement Disorders Society Unified PD Rating Scale (MDS-UPDRS)-II and -III and Hoehn & Yahr (HY)]; and non-motor [MDS-UPDRS-I, University of Pennsylvania Smell Identification Test (UPSIT), Montreal Cognitive Assessment (MoCA), and Epworth Sleepiness Scale (ESS)] scores. Age at diagnosis was set as 0 years, and data were tracked for 15 subsequent years. Results Subjects’ (3,001 PD cases: 2,838 white, 1,843 males) mean age at diagnosis was 60.2±10.3 years and disease duration was 9.9±6.0 years at the baseline evaluation. Participants largely reported independence (S&E, 5y : 86.6±12.3; 10y : 78.9±19.3; 15y : 78.5±17.0) and good quality of life (PDQ-39, 5y : 15.5±12.3; 10y : 22.1±15.8; 15y : 24.3±14.4). Motor scores displayed a linear progression, whereas non-motor scores plateaued ∼10-15 years. Younger onset age correlated with slower overall (S&E), motor (MDS-UPDRS-III), and non-motor (UPSIT/MoCA) progression, and females had better overall motor (MDS-UPDRS-II-III) and non-motor (UPSIT) scores than males. Conclusions Twenty-first century PD patients remain largely independent in the first decade of disease. Female and young age of diagnosis were associated with better clinical outcomes. There are data gaps for non-whites and metrics that gauge non-motor progression for >10 years after diagnosis. ### Competing Interest Statement The authors have declared no competing interest. ### Funding Statement This work was supported in part by the National Institute of Neurological Disorders and Stroke (NS060722, NS082151 and NS112008; XH PI), Penn State College of Medicine Translational Brain Research Center, and Michael J. Fox Foundation for Parkinson's Research (18078; GD PI). ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: AMP-PD () I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes All data produced in the present work are contained in the manuscript

Longitudinal Monitoring of Parkinson's Disease in Different Ethnic Cohorts: The DodoNA and LONG-PD Study

Genetic and phenotypic characterization of Parkinson's disease at the clinic-wide level

Multifactorial assessment of Parkinson's disease course and outcomes using trajectory modeling in a multiethnic, multisite cohort - extension of the LONG-PD study

Identification of Parkinson’s Disease PACE Subtypes and Repurposing Treatments Through Integrative Analyses of Multimodal Data

Monogenic Parkinson's Disease and the Impact of APOE E4: A Case-Control Study

Genome-wide Survival Study Identifies a Novel Synaptic Locus and Polygenic Score for Cognitive Progression in Parkinson’s Disease

Longitudinal immunophenotyping to track motor progression in Parkinson’s Associated with a TH mutation

Eleven Years of Change: Disease Progression in Biomarker-Defined Sporadic Parkinson's Disease

Two Distinct Trajectories of Clinical and Neurodegeneration Events in Parkinson’s Disease

Disease progression strikingly differs in research and real-world Parkinson’s populations

An Integrative Network Approach for Longitudinal Stratification in Parkinson’s Disease

Genome-wide Analysis of Motor Progression in Parkinson Disease

Clinical Progression of Parkinson’s Disease in the Early 21st Century: Insights from AMP-PD Dataset

Longitudinal cognitive decline characterizes the profile of non-PD-manifest GBA1 mutation carriers

Modeling of Parkinson's Disease Progression and Implications for Detection of Disease Modification in Treatment Trials

Genetic analysis and natural history of Parkinson's disease due to the LRRK2 G2019S variant

The Black and African American Connections to Parkinson's Disease (BLAAC PD) study protocol

The STRAT-PARK cohort: a personalized initiative to stratify Parkinson's disease

Parkinson's disease variant detection and disclosure: PD GENEration, a North American study

Disease Progression in Patients with Parkin ‐Related Parkinson's Disease in a Longitudinal Cohort